Donor-Cell Origin High-Risk Myelodysplastic Syndrome Synchronous with an Intracranial Meningioma-Like Tumor, 8 Years after Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia

Secondary neoplasias are well known consequences of radiotherapy or chemotherapy for a primary cancer. In this report, we describe two rare secondary neoplasias occurring in the same patient: a meningioma-like intracranial tumor and high-risk myelodysplastic syndrome (MDS) of donor-cells origin, bot...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in medicine 2017-01, Vol.2017 (2017), p.1-5
Main Authors: Brás, G., Campos Júnior, António, Pinho Vaz, Carlos
Format: Article
Language:English
Subjects:
Biology
Bone marrow
Brain cancer
Cancer
Cancer therapies
Care and treatment
Case Report
Case reports
Chemotherapy
Chronic lymphocytic leukemia
Cytomegalovirus
Diagnosis
Disease
Drug therapy
Engraftment
Hematology
Hematopoietic stem cells
Hemorrhage
Leukemia
Lymphatic leukemia
Lymphocytes
Meningioma
Myelodysplastic syndrome
Myelodysplastic syndromes
Nervous system
NMR
Nuclear magnetic resonance
Patients
Radiation therapy
Remission
Risk factors
Stem cell transplantation
Stem cells
Transplantation
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Secondary neoplasias are well known consequences of radiotherapy or chemotherapy for a primary cancer. In this report, we describe two rare secondary neoplasias occurring in the same patient: a meningioma-like intracranial tumor and high-risk myelodysplastic syndrome (MDS) of donor-cells origin, both diagnosed simultaneously, 8 years after an allogeneic hematopoietic stem cell transplantation (allo-HSCT) for chronic lymphocytic leukemia (CLL). Due to an engraftment failure during the first allo-HSCT of a matched related donor for CLL treatment, the salvage treatment was a second allo-HSCT. At the moment of meningioma-like tumor diagnosis, the patient was pancytopenic due to high-risk MDS, so it was decided to postpone a surgical intervention until hematological improvement. For the high-risk MDS of donor-cells origin the chosen treatment was induction with intensive chemotherapy. Due to refractory disease, the patient was treated with 5-azacitidine and donor-lymphocytes infusion with no response and, finally, a third allo-HSCT of a matched unrelated donor was performed. The patient died 6 months after the third allo-HSCT, in cytogenetic remission but without hematological recovery, due to an intracranial hemorrhage with origin in the meningioma-like tumor.
ISSN:1687-9627
1687-9635
DOI:10.1155/2017/9674385